ArticleStem cell research & therapy2025
TAZ enhances the activity of the AKT signaling pathway to promote adipogenesis of gADSCs.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Mechanobiology of Adipocyte Hypertrophy: Cytoskeletal Remodelling as a Driver of Insulin Resistance in Obesity.Cell biochemistry and function · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Adipose-derived mesenchymal stem cells (ADSCs) possess the capacity for multidirectional differentiation, including differentiation into adipocytes. However, the molecular mechanisms that control adipogenesis are not yet fully understood.Transcriptional co-activator with PDZ-binding motif (TAZ) can act as a molecular rheostat, finely regulating the balance between osteoblast and adipocyte differentiation. In this study, we investigated whether TAZ plays a role in the adipogenesis of goat ADSCs (gADCS). Our results indicated that the expression of TAZ increased during adipogenesis of gADSCs. We established gADSCs cell lines with stable TAZ overexpression and knockdown. We found that TAZ overexpression promoted the adipogenesis of gADSCs, whereas its knockdown inhibited this process. Furthermore, TAZ overexpression and knockdown altered the nuclear expression of Yes-associated protein(YAP) and TAZ. Subsequent analyses indicated that TAZ overexpression increased AKT phosphorylation levels. Moreover, treatment with a PI3K inhibitor (LY294002) abrogated the TAZ-induced increase in adipogenesis, suggesting that TAZ regulates the adipogenesis of gADSCs via the PI3K/AKT pathway. Collectively, our results indicate that TAZ promotes the adipogenesis of gADSCs by enhancing the activity of the PI3K/AKT signaling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.